Under the agreement, Particle Sciences is responsible for design, formulation and cGMP supplies. Actavis will have responsibility for clinical testing, regulatory filings and marketing. Particle Sciences CEO Mark
Once-daily PREZISTA is indicated for the treatment of HIV-1 in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA is always taken with and at the
The patent with the latest date of expiry is 2030, without taking into account patent term extension. The three patent applications allowed by the USPTO cover composition of
NESP, a long-acting erythropoiesis stimulating agent, was initially approved in July 2007. NESP is highly recognized for its safety and efficacy for treating anemia of chronic kidney disease
The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
NCCN ORP vice president Diane Paul said this grant from Astellas and Medivation gives investigators at NCCN Member Institutions a remarkable opportunity to study the effectiveness of enzalutamide
The announcement means a streamlining of the complex process of clinical research studies, making the setting up of such studies faster and easier by reducing bureaucracy and duplication.
This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia. This joint project
Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the
Hugel is the leading producer of anti-aging and Botulinum Toxin products in South Korea and Asia. Croma-Pharma managing director and owner Andreas Prinz noted that the company is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.